JP2020512315A5 - - Google Patents

Download PDF

Info

Publication number
JP2020512315A5
JP2020512315A5 JP2019550579A JP2019550579A JP2020512315A5 JP 2020512315 A5 JP2020512315 A5 JP 2020512315A5 JP 2019550579 A JP2019550579 A JP 2019550579A JP 2019550579 A JP2019550579 A JP 2019550579A JP 2020512315 A5 JP2020512315 A5 JP 2020512315A5
Authority
JP
Japan
Prior art keywords
hydrogen
deuterium
disease
fibrosis
compound according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2019550579A
Other languages
English (en)
Japanese (ja)
Other versions
JP7200120B2 (ja
JP2020512315A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2018/022544 external-priority patent/WO2018170200A1/en
Publication of JP2020512315A publication Critical patent/JP2020512315A/ja
Publication of JP2020512315A5 publication Critical patent/JP2020512315A5/ja
Application granted granted Critical
Publication of JP7200120B2 publication Critical patent/JP7200120B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2019550579A 2017-03-16 2018-03-15 Mk2阻害剤として有用なヘテロアリール化合物 Active JP7200120B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762472019P 2017-03-16 2017-03-16
US62/472,019 2017-03-16
PCT/US2018/022544 WO2018170200A1 (en) 2017-03-16 2018-03-15 Heteroaryl compounds useful as mk2 inhibitors

Publications (3)

Publication Number Publication Date
JP2020512315A JP2020512315A (ja) 2020-04-23
JP2020512315A5 true JP2020512315A5 (https=) 2021-04-30
JP7200120B2 JP7200120B2 (ja) 2023-01-06

Family

ID=63523329

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019550579A Active JP7200120B2 (ja) 2017-03-16 2018-03-15 Mk2阻害剤として有用なヘテロアリール化合物

Country Status (4)

Country Link
US (2) US11124525B2 (https=)
EP (1) EP3596083A4 (https=)
JP (1) JP7200120B2 (https=)
WO (1) WO2018170200A1 (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS62017B1 (sr) 2014-09-17 2021-07-30 Celgene Car Llc Mk2 inhibitori i njihova upotreba
US11230551B2 (en) 2017-03-16 2022-01-25 Celgene Car Llc Deuterated analogs of MK2 inhibitors and uses thereof
JP7282039B2 (ja) 2017-03-16 2023-05-26 セルジーン シーエーアール エルエルシー Mk2阻害剤、その合成、およびそれに至るまでの中間体
JP7200120B2 (ja) 2017-03-16 2023-01-06 セルジーン シーエーアール エルエルシー Mk2阻害剤として有用なヘテロアリール化合物
WO2018170204A1 (en) * 2017-03-16 2018-09-20 Celgene Car Llc 9,10,11,12-tetrahydro-8h-[1,4]diazepino[5',6':4,5]thieno[3,2-f]quinolin-8-one compounds and uses thereof
US10882867B2 (en) 2017-03-16 2021-01-05 Celgene Car Llc Forms and compositions of a MK2 inhibitor
CN114364681A (zh) * 2019-05-17 2022-04-15 西建卡尔有限责任公司 治疗mk2介导的病症的方法
KR20230142529A (ko) 2021-02-01 2023-10-11 셀진 코포레이션 Mk2 억제제, 이의 합성, 및 이의 중간체
TW202328141A (zh) * 2021-08-27 2023-07-16 大陸商瑞石生物醫藥有限公司 喹啉并呋喃衍生物及其用途
MX2024008704A (es) 2022-01-14 2024-07-22 Shanghai Hansoh Biomedical Co Ltd Derivado policiclico que contiene piridina, y metodo de preparacion de este y uso de este.
CN115925718A (zh) * 2022-12-27 2023-04-07 瑞石生物医药有限公司 一种四环内酰胺衍生物及其用途
WO2024229401A2 (en) * 2023-05-04 2024-11-07 Matchpoint Therapeutics Inc. Diazepino-thieno-quinoxaline compounds and their use in therapy

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5015778A (en) 1989-12-18 1991-05-14 The Dow Chemical Company Catalytic method to produce hydroxy substituted arylophenones
CN1087725C (zh) * 1994-03-25 2002-07-17 同位素技术有限公司 用氘代方法增强药物效果
US5441946A (en) 1994-04-14 1995-08-15 Rhone-Poulenc-Rorer Pharmaceuticals, Inc. Phosphonate derivatives of lipophilic amines
TW200413273A (en) 2002-11-15 2004-08-01 Wako Pure Chem Ind Ltd Heavy hydrogenation method of heterocyclic rings
CN1747949A (zh) 2002-12-20 2006-03-15 法马西亚公司 无环吡唑化合物
WO2005105814A1 (en) 2004-04-28 2005-11-10 Incyte Corporation Tetracyclic inhibitors of janus kinases
CN101687869A (zh) 2007-07-16 2010-03-31 诺瓦提斯公司 作为mk2抑制剂的四环内酰胺衍生物
WO2011153553A2 (en) 2010-06-04 2011-12-08 The Regents Of The University Of California Methods and compositions for kinase inhibition
KR20130124291A (ko) 2010-07-02 2013-11-13 길리애드 사이언시즈, 인코포레이티드 Hiv 항바이러스 화합물로서의 2-퀴놀리닐-아세트산 유도체
BR112013010310A2 (pt) 2010-10-29 2016-11-29 Pfizer inibidores de acetil-coa carboxilase de lactama n1/n2
HK1210696A1 (en) 2012-07-11 2016-05-06 Nimbus Iris, Inc. Irak inhibitors and uses thereof
JP2016518316A (ja) 2013-03-15 2016-06-23 セルジーン アビロミクス リサーチ, インコーポレイテッド Mk2阻害剤およびそれらの使用
WO2016032882A1 (en) * 2014-08-25 2016-03-03 Stc.Unm Inhibition of mk2 in the treatment of cancer
RS62017B1 (sr) 2014-09-17 2021-07-30 Celgene Car Llc Mk2 inhibitori i njihova upotreba
WO2018170204A1 (en) 2017-03-16 2018-09-20 Celgene Car Llc 9,10,11,12-tetrahydro-8h-[1,4]diazepino[5',6':4,5]thieno[3,2-f]quinolin-8-one compounds and uses thereof
JP7200120B2 (ja) 2017-03-16 2023-01-06 セルジーン シーエーアール エルエルシー Mk2阻害剤として有用なヘテロアリール化合物
JP7282039B2 (ja) * 2017-03-16 2023-05-26 セルジーン シーエーアール エルエルシー Mk2阻害剤、その合成、およびそれに至るまでの中間体
US11230551B2 (en) 2017-03-16 2022-01-25 Celgene Car Llc Deuterated analogs of MK2 inhibitors and uses thereof
US10882867B2 (en) 2017-03-16 2021-01-05 Celgene Car Llc Forms and compositions of a MK2 inhibitor
CN114364681A (zh) 2019-05-17 2022-04-15 西建卡尔有限责任公司 治疗mk2介导的病症的方法
US20230255979A1 (en) 2020-07-24 2023-08-17 Bristol-Myers Squibb Company Methods of treating acute respiratory disorders
KR20230142529A (ko) 2021-02-01 2023-10-11 셀진 코포레이션 Mk2 억제제, 이의 합성, 및 이의 중간체

Similar Documents

Publication Publication Date Title
JP2020512315A5 (https=)
JP2020511468A5 (https=)
JP2020514361A5 (https=)
JP2020514360A5 (https=)
ES2988336T3 (es) Un agente antineoplásico 1-((4-(4-fluoro-2-metil-1H-indol-5-iloxi)-6-metoxiquinolin-7-iloxi)metil)ciclopropanamina, su forma cristalina y sus sales
JP2024113019A5 (https=)
JP2019524660A5 (https=)
JP2013545812A5 (https=)
JP2011513485A5 (https=)
JP2008510762A5 (https=)
CA3019450A1 (en) Indoleamine 2,3-dioxygenase inhibitor, preparation method therefor, and application
HRP20230466T1 (hr) Kristalni čvrsti oblici bet inhibitora
Chen et al. Controlled crystallization of anhydrous guanine β nano-platelets via an amorphous precursor
JP2009502961A5 (https=)
TW201906826A (zh) 奧美卡替莫卡必爾的合成
WO2015161781A1 (zh) 一种核苷类似物及其中间体的制备方法
CN117486959A (zh) 磷酸酯衍生物的合成
JPWO2020033955A5 (https=)
JP2022105096A (ja) 細胞傷害性ベンゾジアゼピン誘導体の調製方法
WO2009082846A1 (fr) Dérivé hydroxyle de la capécitabine, ses procédés de préparation et ses utilisations pour préparer la capécitabine
TWI703163B (zh) 舒更葡糖鈉之製備方法及其晶型
CN112752749B (zh) 作为pd-l1免疫调节剂的氟乙烯基苯甲酰胺基化合物
CN120752230A (zh) Kif18a的抑制剂及其用途
CN112585124B (zh) 用于合成sglt抑制剂的中间体的制备方法
WO2012139522A1 (zh) 去氢木香烃内酯衍生物,其药物组合物及其制备方法和用途